 AGOURA HILLS, Calif., March 10, 2022 GLOBE NEWSWIRE -- Oncotelic Therapeutics, Inc. Oncotelic or the Company OTCQB:OTLC , a leading developer of TGF-β therapeutics for oncology and virology, today announced that it will present new studies on its TGF- β program at the American Association for Cancer Research AACR Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana. 